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Abstract: Cerebral amyloid angiopathy (CAA) is typified by the cerebrovascular deposition of
amyloid. Currently, there is no clear understanding of the mechanisms underlying the contribution of
CAA to neurodegeneration. Despite the fact that CAA is highly associated with the accumulation of
Aβ, other types of amyloids have been shown to associate with the vasculature. Interestingly, in many
cases, vascular amyloidosis has been associated with an active immune response and perivascular
deposition of hyperphosphorylated tau. Despite the fact that in Alzheimer’s disease (AD) a major
focus of research has been the understanding of the connection between parenchymal amyloid plaques,
tau aggregates in the form of neurofibrillary tangles (NFTs), and immune activation, the contribution of
tau and neuroinflammation to neurodegeneration associated with CAA remains understudied. In this
review, we discussed the existing evidence regarding the amyloid diversity in CAA and its relation to
tau pathology and immune response, as well as the possible contribution of molecular and cellular
mechanisms, previously associated with parenchymal amyloid in AD and AD-related dementias, to
the pathogenesis of CAA. The detailed understanding of the “amyloid-tau-neuroinflammation” axis
in the context of CAA could open the opportunity to develop therapeutic interventions for dementias
associated with CAA that are currently being proposed for AD and AD-related dementias.
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1. Introduction
Alzheimer’s disease (AD), the most common form of dementia, is characterized by the extracellular
deposition of parenchymal β-amyloid (Aβ), intracellular accumulation of tau as neurofibrillary tangles
(NFTs), synaptic loss, and significant inflammation [1,2]. Cerebral amyloid angiopathy (CAA) is
typified by the cerebrovascular deposition of amyloid and has a close molecular relationship with AD,
but remains clinically distinct. Vascular amyloid accumulation is identified in an estimated 85%–95% of
individuals with AD [3,4], positioning CAA as one of the strongest vascular contributors to age-related
cognitive decline [5,6]. Despite this high prevalence, the severity of CAA is highly variable in AD
and therefore does not seem to strongly depend on the severity of AD pathology (e.g., CERAD and
Braak stages) [7–9]. The mechanisms responsible for CAA pathogenesis and its downstream effects
on the brain are complex and not completely understood. As for the origin of amyloid in CAA, the
smooth muscle cells were originally proposed as the source of cerebral amyloid. Nevertheless, the sole
contribution of smooth muscle cells to CAA is made less likely by the existence of amyloid deposits in
capillaries in CAA patients. Based on this, it has been proposed that the amyloid is indeed derived
from neurons and is drained along the perivascular interstitial fluid pathway of the brain parenchyma
and leptomeninges, depositing along the vessels [10,11]. This perivascular drainage impairment sets
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in motion a self-reinforcing pathway by which worsening vascular amyloid accumulation leads to
the activation of vascular injury pathways. This results in the impairment of vascular physiology,
leading to a further increase in amyloid accumulation [12,13]. The damaged endothelium can produce
proinflammatory cytokines that magnify neuroinflammation, glial activation, and secondary injury,
leading to blood–brain barrier (BBB) breakdown [14]. Despite the fact that CAA is highly associated
with the accumulation of Aβ [4], other types of amyloids have been shown to associate with the
vasculature, suggesting that CAA should be considered as a group of biochemically and genetically
diverse disorders unified by the accumulation of amyloid deposits in the walls of arterial blood vessels,
and, in some cases, also in capillaries of the CNS parenchyma and leptomeninges [15–17]. Interestingly,
in many cases, vascular amyloidosis is associated with severe neurofibrillary tau pathology, which is
more pronounced around amyloid-laden blood vessels [18–20].
Over the past decades, a major focus of research has been on understanding the molecular and
cellular connections between parenchymal amyloid, tau aggregation, and neuroinflammation, while
the correlation between vascular amyloid pathology with tau aggregation and neuroinflammation has
mainly been reported based on neuropathological observations.
In this review, we will summarize the existing evidence regarding the amyloid diversity in CAA
and its relation to tau pathology and neuroinflammation, as well as discuss the possible contribution
of molecular and cellular mechanisms, previously associated with parenchymal amyloid, to the
pathogenesis of CAA.
2. The Diversity of Amyloid in CAA
Though CAA is defined by the accumulation of amyloid in the vasculature, distinct types of
amyloids have been reported to deposit in blood vessels, as seen in Table 1. Broadly, there are
Aβ-related CAAs and other amyloid-related CAAs [4,21–23]. In Aβ-CAA, the amyloidogenic forms of
Aβ (Aβ40 and Aβ42) are produced from the processing of the 695 aa amyloid precursor protein (APP)
by the sequential proteolytic cleavage of a β-secretase (BACE) and a γ-secretase-presinilin complex
in what is called the amyloidogenic pathway, since it produces peptides that are prone to aggregate.
This differs from the more physiological non-amyloidogenic pathway, where the sequential cleavage is
produced by an α-secretase first and later by the γ-secretase-presinilin complex [24–26]. The transition
from soluble to amyloidogenic nature of these Aβ peptides is explained by the conformational change
given by the increase in the content of β-sheets in their structure, favoring their deposition as oligomers
to finally form aggregated fibrils. The main type of Aβ accumulated in the vasculature is Aβ40 and to
a lesser extent Aβ42 [3]. The vascular accumulation of amyloid species promotes the weakening of the
blood vessel wall, challenging its integrity and leading to infarcts and hemorrhages [4,27]. This also
causes smooth muscle degeneration and neurotoxicity [28].
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Table 1. Sporadic and hereditary cerebral amyloid angiopathy (CAA) forms.
Amyloid Gene Precursor Protein Mutation Disease
Aβ APP Amyloid precursor protein none Sporadic CAA [21,22]
Aβ APP Amyloid precursor protein E693Q Hereditary Cerebral Hemorrhage withAmyloidosis Dutch type [29–32]
Aβ APP Amyloid precursor protein E693K Hereditary Cerebral Hemorrhage withAmyloidosis Italian type [33]
Aβ APP Amyloid precursor protein E693G Hereditary Cerebral Hemorrhage withAmyloidosis Arctic type [34]
Aβ APP Amyloid precursor protein E693∆ Hereditary Cerebral Hemorrhage withAmyloidosis Osaka type [35,36]
Aβ APP Amyloid precursor protein A692G Hereditary Cerebral Hemorrhage withAmyloidosis Flemish type [37]
Aβ APP Amyloid precursor protein D694N Hereditary Cerebral Hemorrhage withAmyloidosis Iowa type [38]
Aβ APP Amyloid precursor protein L705V Hereditary Cerebral Hemorrhage withAmyloidosis Piedmont type [39]
Aβ APP Amyloid precursor protein A713T Hereditary Cerebral Hemorrhage withAmyloidosis Italian type [40,41]
Aβ APP Amyloid precursor protein T714I Hereditary Cerebral Hemorrhage withAmyloidosis Austrian type [42]
Aβ APP Amyloid precursor protein T714A Hereditary Cerebral Hemorrhage withAmyloidosis Iranian type [43]
ABri BRI2 British Amyloid protein 799A>T Familial British Dementia [18,44–47]
ADan BRI2 Danish Amyloid protein 787_796dupTTTAATTTGT Familial DanishDementia [18,45,46,48–50]
ACys CST3 Cystatin C L68Q Hereditary Cerebral Hemorrhage withAmyloidosis Islandic type [51–53]
ATTR TTR Transthyretin D18G Meningovascular amyloidosis Hungarianvariant [54–57]
ATTR TTR Transthyretin V30G Meningovascular amyloidosis Ohiovariant [58–60]
ATTR TTR Transthyretin Y69H Meningovascular amyloidosis rarevariant [61–64]
ATTR TTR Transthyretin A25T Meningovascular amyloidosis rarevariant [65,66]
ATTR TTR Transthyretin V30M Meningovascular amyloidosis rarevariant [67,68]
ATTR TTR Transthyretin T49P Meningovascular amyloidosis rarevariant [69]
ATTR TTR Transthyretin L58R Meningovascular amyloidosis rarevariant [70]
ATTR TTR Transthyretin F64S Meningovascular amyloidosis rarevariant [71]
ATTR TTR Transthyretin Y114C Meningovascular amyloidosis rarevariant [72]
ATTR TTR Transthyretin L12P Meningovascular amyloidosis rarevariant [73]
ATTR TTR Transthyretin G53R Meningovascular amyloidosis rarevariant [74]
AGel GSN Gelsolin D187N or D187Y Hereditary gelsolin amyloidosis orfamilial amyloidosis Finnish type [75–77]
PrPSc PRNP Prion protein Y145stop Gerstmann–Sträussler–Scheinkersyndrome variant [20]
PrPSc PRNP Prion protein Y163stop Gerstmann–Sträussler–Scheinkersyndrome variant [78]
2.1. Aβ Amyloid in CAA
Aβ-CAA can be divided into two main groups: a sporadic type (SCAA) and a hereditary
type. SCAA constitutes the most common and the majority of the cases of Aβ-CAAs. In these, an
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age-related failure of elimination of amyloidogenic Aβ peptides is the most important risk factor for
their accumulation in the vasculature [79]. On the contrary, in hereditary Aβ-CAAs, specific mutations
are directly related with the vascular accumulation of Aβ. These are the cases of several rare familial
genetic conditions termed hereditary hemorrhages with amyloidosis, caused by a mutation on the APP
gene located on chromosome 21 [21,22,80,81]. The most studied of these is the Dutch type, where the
substitution of glutamic acid for glutamine at codon 693 leads to the production of an aberrant Aβ40
that aggregates and accumulates rapidly in arterioles of meninges and brain cortex [29–32]. Three other
less studied mutations of this same codon are the Italian, the Arctic, and the Osaka types. The first one
presents a substitution of glutamic acid for lysine and the second for glycine, both upregulating an
aberrant form of Aβ40 [33,34]. In the third one, the lack of a glutamate as a result of a whole deletion of
codon 693 leads to the production of highly oligomeric Aβ40 and Aβ42 [35,36]. Mutations on other
codons are reported to cause synthesis of abnormal forms of Aβ as well. An alanine replacement
by glycine at codon 692 is present in the Flemish type. In this case, the change affects the cleavage
site of the α-secretase on APP, shifting it towards β-secretase processing, upregulating both Aβ40
and Aβ42 [37]. On the other hand, in the Iowa type, a substitution of asparagine for aspartic acid at
codon 694 causes an increase only of Aβ40 [38]. A substitution of leucine for valine at codon 705 is
identified as the Piedmont variant, showing severe Aβ40 and Aβ42 vascular deposits [39]. Another
Italian type was reported affecting codon 713, where the replacement of alanine for threonine causes
extensive Aβ40 aggregation [40,41]. Additionally, codon 714 can be differently mutated giving rise to
the Austrian and a rare Iranian type. In the first case, the mutation presents a change in a threonine for
an isoleucine, directly affecting the γ-secretase cleavage site, increasing the Aβ42/Aβ40 ratio [42]. In the
second case, the substitution is for alanine, and is likely to alter APP processing such that more Aβ42 is
produced [43].
2.2. Non-Aβ Amyloid in CAA
Although the Aβ peptide is by far the most common amyloid accountable for the vascular
accumulation and damage, other types of amyloid have been shown to cause the same effects in
hereditary types of CAA [21,22]. This is the case of Familial British Dementia (FBD) and Familial Danish
Dementia (FDD) [18,44,48]. Both conditions show progressive loss of cognitive functions, dementia
and ataxia. Neuropathologically, FDD closely resembles FBD regarding its vascular amyloidosis;
however, parenchymal deposits found in the hippocampus of patients with FDD were Congo red
and Thioflavine-S (ThioS)-negative [19]. Interestingly, brains from affected individuals present tau
aggregation [45]. Common to both FBD and FDD is the involvement of mutations on the BRI2 gene on
chromosome 13 that encodes the membrane-bound 266 aa BRI2 protein. Its physiological cleavage by
protein convertases generates the soluble 23 aa BRI2-23 peptide [18,44,46]. However, two different
mutations on the BRI2 gene will lead to the production of a mutated form of BRI2. In individuals affected
by FBD, a point mutation eliminates the normal stop codon on the gene. In FDD, individuals show a
10-nucleotide duplication causing a frameshift. In both cases, there is a read extension and a subsequent
addition of 11 aa. The processing of these abnormal 277 aa mutated Bri2 proteins produce the 34 aa
ABri and ADan amyloids in FBD and FDD respectively, both of which are highly amyloidogenic
and neurotoxic [22,46,47,49,82]. In addition, it has been reported that ADan can be deposited in
combination with Aβ in blood vessels of the brain parenchyma [44]. In the case of cerebral hemorrhage
with amyloidosis of the Islandic type (HCHWA-I), the nature of extensive deposits of amyloid fibrils is
the accumulation of the mutated form of the cystatin C transmembrane protein [51,52]. The mutation
corresponds to a single nucleotide substitution at codon 68 of the CST3 gene on chromosome 20 [51,83].
Remarkably, immunohistochemical analysis of brains of patients with AD revealed that this mutated
peptide colocalizes with Aβ in parenchymal and vascular amyloid deposits [53]. Other mutated
proteins that can accumulate in an amyloidogenic fashion are transthyretins (TTRs), gelsolin, and the
prion protein (PrP) [21,22]. Several different mutations, see Table 1, on the TTR gene on chromosome 18
produce an amyloidogenic form of the TTR protein that aggregates extensively in leptomeninges [58].
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This condition is termed meningovascular amyloidosis [22,80]. Interestingly, one of the cases analyzed
showed distinctive aggregates of phospho-tau subjacent to TTR amyloid deposits in all regions of the
neocortex and primary motor and striate cortices, indicating a potential link between TTR amyloid and
cortical tauopathy [61]. In hereditary gelsolin amyloidosis, also called familial amyloidosis Finnish
type (FAF), a mutation in the GSN gene on chromosome 9 causes gelsolin to be abnormally cleaved,
generating several small fragments with amyloidogenic properties [75–77]. Finally, the amyloidogenic
variant of the PrP (PrPSc) is caused by a single point mutation at codon 145 in the PRNP gene on
chromosome 20, resulting in a premature stop codon that alters its glycosylation and signal sequence
sites [20], leading to an increase of β-sheet structures in the protein [84]. These characteristics allows
PrPSc to increase its propensity to aggregate in the vasculature [85]. A mutation at codon 163 has
also been reported to produce a PrPSc [22,78]. Overall, these observations suggest that CAA is
a heterogeneous group of CNS disorders, characterized by the dynamic accumulation of different
amyloid species in the vasculature.
3. Perivascular Tau Aggregation and Its Interplay with Cerebrovascular Damage and CAA
Pathological aggregation of the microtubule-associated protein tau and the preponderance of
NFTs or other inclusions containing tau are defining histopathological features of AD and many
neurodegenerative diseases collectively known as tauopathies [86]. Interestingly, accumulation
of tau has been detected in cerebrovascular pathologies associated with endothelial dysfunction
and cognitive impairment [87,88]. Noteworthy, several studies have suggested that pathological
changes of tau in neurons can impact brain endothelial cell biology, altering the integrity of the
brain’s microvasculature [89,90]. For instance, it has been shown that vessel wall remodeling of
leptomeningeal arteries is an early-onset, tau pathology-dependent process, which may potentially
contribute to downstream CAA-dependent microvascular pathology in AD patients [90]. Even more,
other studies have demonstrated an increase of BBB permeability and the accumulation of tau oligomers
in the cerebral microvasculature of human patients with progressive supranuclear palsy (PSP) [91,92],
emphasizing the role of tau aggregates in the functional and structural integrity of the cerebral
vasculature. In a similar fashion, tau-overexpressing mice develop changes to blood vessels including
abnormal, spiraling morphologies, reduced blood vessel diameter, and increased overall blood vessel
density in the cortex [89]. In a different mouse model for tauopathies, BBB dysfunction emerges at the
same time that perivascular tau emerges around major hippocampal blood vessels. However, when
tau expression is suppressed, BBB integrity is preserved, suggesting that the BBB can be stabilized in a
tauopathic brain by reducing tau levels [93]. Overall, these studies suggest a strong relation between
tau pathology and vascular damage, and how tau aggregation is not a unidirectional event where
vascular damage initiates a series of events that triggers tau aggregation, but is rather a vicious cycle
where tau pathology enhances vascular damage.
In many cases, vascular amyloidosis is accompanied by significant perivascular tau
pathology [19,20,94], supporting a unifying pathological mechanism in which vascular accumulation
of amyloidogenic peptides triggers a complex pathological cascade leading to tau accumulation and
neurodegeneration. However, it remains to be determined whether abnormal tau phosphorylation is the
consequence of CAA or an independent disease characteristic. Recently, we biochemically demonstrated
an increase of hyperphosphorylated forms of tau in the Tg-FDD mouse model characterized by vascular
deposition of ADan amyloid [95]. This increase was only observed in certain phospho-tau epitopes,
but not others that have been associated with tau NFTs in AD, suggesting that the process of tau
hyperphosphorylation associated with CAA deposits could be different from the hyperphosphorylation
of tau associated with parenchymal deposition of amyloid [96]. In the same study, we observed how
these perivascular tau aggregates in the vicinity of vascular amyloid were associated with activated
astrocytes [95]. Interestingly, astrocytes play a key role in maintaining the BBB via astrocytic endfeet
directly opposed to vascular endothelial cells [96], and tau has been shown to accumulate in these
endfeet in tauopathies [97,98], including perivascular astrocytic tau deposits in CAA patients [19].
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Even more, the presence of perivascular tau aggregates has been reported in patients with chronic
trauma encephalopathy (CTE) [99,100]. These tau deposits in CTE were also associated with activated
astrocytes [99]. These results suggest that vascular damage, independent of its cause (amyloid
accumulation or CTE), could induce an astrocytic response that triggers tau aggregation.
Previous studies have shown how endogenous WT tau appears to be required for parenchymal
Aβ-amyloid accumulation and ApoE4 to cause synaptic, network, and cognitive deficits in mouse
models of AD [101–103]. Significantly, the removal of endogenous tau expression in a mouse model
for Parkinson’s disease, characterized by the aggregation of mutant alpha-synuclein, completely
ameliorates cognitive dysfunction and concurrent synaptic deficits without affecting alpha-synuclein
expression or accumulation of selected toxic alpha-synuclein oligomers [104]. Tau ablation has also
been shown to attenuate motor abnormalities in a Huntington’s disease (HD) mouse model [105] and
prevent deficits in spatial learning and memory after repeated mild frontal impact in WT mice [106].
Furthermore, tau reduction has the ability to block epileptogenesis of diverse causes, including epileptic
activity triggered by pharmacological blockade of GABAA channels [104,107], genetic ablation of
the voltage-gated potassium channel subunit Kv1.1 [108], depletion of ethanolamine kinase or of the
K+–Cl− cotransporter [108], or depletion of the voltage-gated sodium channel subunit Nav1.1 [109].
The mechanisms underlying these beneficial effects of tau reduction remain to be determined [86].
New evidence suggests that tau could be involved in a common pathway for neurodegeneration
triggered by cerebrovascular abnormalities and parenchymal amyloid pathologies [88]. Recently, a
novel study showed how exposing mice to a salt-rich diet not only leads to cognitive dysfunction
associated with a nitric oxide deficit in cerebral endothelial cells and cerebral hypoperfusion, but also
induces hyperphosphorylation of tau [110]. Remarkably, the authors did not observe salt-induced
cognitive impairment in tau-null mice or in mice treated with anti-tau antibodies, despite the persistent
cerebral hypoperfusion and neurovascular dysfunction [110].
Thus, considering the dependency of parenchymal amyloid for tau to exert neurotoxicity and
the relevance of tau in several pathogenesis associated with neurovascular dysfunction, it is feasible
to suggest that vascular amyloid would also depend on tau to trigger neurodegeneration and that
partial tau reduction could be considered a feasible approach for the treatment of dementias associated
with CAA.
4. The Implication of AD Immune-Risk Factors and Glial Response in CAA
The aggregation and accumulation of vascular amyloid has long been recognized as a major
contributor to neuroinflammation, playing a fundamental role in the pathogenesis of AD. However,
the majority of studies addressing this issue have focused on parenchymal amyloid deposition
with little attention given to CAA [111–114]. Data from human patients and in vivo models for
CAA suggest that damage to vessel walls activates the endothelium, facilitates the infiltration of
monocytes/macrophages and incites glial reactivity, increasing the production of pro-inflammatory
cytokines [115–119]. Novel genetic studies suggest that glial reactivity and innate immune cell activation
may drive AD pathogenesis through a vascular-related mechanism [120]. Given the relationship
between neuroinflammation and vascular damage, it is imperative to understand in detail the role of
neuroinflammatory pathways associated with CAA pathogenesis.
The neurovascular unit (NVU) is a complex structure organized by endothelial cells, intimately
associated with pericytes and astrocytic endfeet to form the BBB. Parenchymal cells including
excitatory neurons, regulatory interneurons and microglia actively interact with the NVU [121].
As central components of the NVU, pericytes represent the first line of immunological defense as
antigen-presenting cells, playing a pivotal role in the maintenance of the BBB and microvascular
stability. They also participate in capillary constriction and dilation, regulating cerebral blood flow,
immune cell entry, and clearance of macromolecules from the brain’s interstitial fluid [122,123]. When
CAA occurs, pericytes display degenerative features influencing BBB breakdown, microaneurysms,
neuroinflammation, and neurodegeneration [124–127]. When exposed to Aβ40, pericytes exhibit an
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increase in the activity of caspases-3 and -7, reducing their viability and promoting tau pathology
that develops into early neuronal loss and cognitive changes [124]. Alongside pericytes, perivascular
macrophages (PVM) are important immunoregulatory cells performing phagocytosis and responding
to transient CNS inflammation [128]. PVM are distinguished from microglia by their expression
of CD36, CD206, and acid phosphatase. They have a high rate of turnover and are involved in
the movement of solutes, infectious agents and immune cells from the blood to the brain [129–131].
The depletion of PVM by directly injecting clodronate, a compound used to study innate responses to
CNS injuries, into the left lateral ventricle of four-month-old TgCRND8 mice results in a significant
increase in CAA in cortical and leptomeningeal blood vessels [132]. On the other hand, the sustained
stimulation of PVM by injecting chitin, a long-chain polymer of N-Acetylglucosamine, caused a
significant reduction of ThioS-labeled cortical blood vessels and CAA load [133,134]. It has been
suggested that PVM requires the C-C chemokine receptor type 2 (CCR2), a receptor involved in the
regulation of macrophage migration and infiltration, to remove amyloid from the brain, since APPswe
CCR2−/− mice showed a drastic impairment in Aβ clearance and amplified CAA [135].
4.1. Microgliosis in CAA
Besides PVM, microglia are also important regulators of neuroinflammation, releasing a variety
of proinflammatory and cytotoxic products in response to cerebral insult or injury. In AD patients
and AD mouse models, microglia clusters around plaques and vascular amyloid, moving toward
newly formed plaques within 24 h of their formation as well as toward existing plaques [136,137],
displaying an activated phenotype capable of producing cytokines and chemokines such as IL-1, IL-6,
TNF-α, TGF-β1, TGF-β2, MIP-1α, and MCP-1, enriching the brain’s neuroinflammatory profile [138].
Several studies have investigated the targeted elimination of microglial in 5xFAD mice through
inhibition of colony stimulating factor 1 receptor (CSF1R), a microglial chemokine receptor, and showed
that chronic microglial elimination at advanced stages of pathology does not alter amyloid-β levels
or plaque load; however, it does rescue dendritic spine loss and prevent neuronal loss, as well as
decrease overall neuroinflammation [139]. Surprisingly, elimination of microglia in the initial stages
of the disease, during the plaque-forming period, appears to play a role in the pathogenesis of CAA
as the sustained elimination of microglia parallels the loss of parenchymal plaque deposition and
results in an immense shift in CAA pathology suggesting one function of microglia in the normal
brain is to protect from CAA [140]. Numerous studies have focused on targeting plaque elimination
through passive immunization and opsonization by microglia/macrophages through the peripheral
administration of anti-Aβ antibodies. These studies have shown potential beneficial effects on plaque
clearance and cognitive improvement; however, there are also toxic effects such as CAA-associated
hemorrhage [141–149]. Additionally, the targeting of certain scavenger receptors expressed in innate
immune cells and cerebral blood vessels has shown to have therapeutic effects for CAA. This is the
case of CD36, a critical innate immune receptor present in endothelial cells and microglia/macrophages,
involved in a key signaling pathway through which Aβ exerts its deleterious vascular effects through
the production of reactive oxygen species. APPswe mice with a genetic deletion of CD36 showed
reduced CAA burden, improved neurovascular function, reduced smooth muscle cell fragmentation,
a selective reduction in Aβ40 plaque load leaving Aβ42 amyloid levels unchanged, and improved
cognitive performance, suggesting improved cerebrovascular health is able to preserve cognitive
function irrespective of parenchymal amyloid burden [150].
4.2. Astrogliosis in CAA
At the same time, astrocytes also have the ability to respond to and influence immune and
inflammatory responses following insults such as excitotoxicity, ischemia, apoptosis, necrosis, and
inflammatory cues. This is achieved by undergoing a pronounced transformative state called ‘reactive
astrogliosis’, regulating inflammatory responses that can be either neuroprotective or neurotoxic and
participating in migratory, phagocytic, and proteolytic activity [151–156]. The interplay between
Int. J. Mol. Sci. 2019, 20, 6319 8 of 19
apolipoprotein E (ApoE), Aβ, and astrocytes has gained important attention as ApoE, the most abundant
apolipoprotein in the brain, is produced by astrocytes and has been widely confirmed to influence lipid
metabolism and the processing, accumulation, and clearance of Aβ. Additionally, the ApoE4 allele
mutation is the strongest genetic risk factor for both AD and CAA [157–159]. ApoE-deficient astrocytes
lose their ability to internalize and degrade deposited Aβ peptides [160], with evidence suggesting
that Aβ40 is internalized in vivo preferentially by astrocytes, not microglia [161,162]. The role of ApoE
in CAA pathogenesis has gained important attention as it was observed that APPswe mice expressing
human ApoE4 show substantial CAA pathology, with very little parenchymal plaque deposition,
as well as an early increase in the Aβ40/42 ratio, demonstrating that once Aβ fibrillogenesis occurs,
ApoE4 expression results in a shift in the amyloid deposition from parenchyma to the vasculature [163].
In addition to ApoE, immunohistochemistry from human AD cases has also revealed a relationship
of amyloid with apolipoprotein J or clusterin (ApoJ or CLU) and apolipoprotein A-I (ApoA-I), both
with implications in CAA pathology [164]. CLU is the second major apolipoprotein produced by
astrocytes, having roles in the aggregation, toxicity and BBB transport of Aβ, suggesting a strong role
in CAA regulating the balance between Aβ deposition and clearance [165,166]. Additionally, loss of
CLU in APP/PS1 mice results in a marked decrease in plaque deposition in the brain parenchyma and
a striking increase in CAA, suggesting that the absence of CLU shifts Aβ to perivascular drainage
pathways, resulting in fewer parenchymal plaques. To this extent, it was observed that adding CLU
exogenously reduces Aβ40 and Aβ42 interactions with cerebral vessels [166]. ApoA-I has also been
linked to AD pathology, binding to circulating Aβ peptides and occasionally associating with senile
plaques [164,167]. Complete loss of ApoA-I increases cortical and hippocampal CAA pathology and
astrogliosis in APP/PS1 mice, boosting both neuro and vascular inflammatory markers, specifically
IL-1β, PDGFRβ, GFAP, and ICAM-1. These mice also showed an increase in GFAP-positive astrocytes
associated with the cerebrovasculature [168]. ApoA-I could be an interesting target for a CAA-directed
therapy as it was observed that APP/PS1 mice overexpressing ApoA-I or injection of ApoA-I reduced
both astrogliosis and cerebral amyloid burden. Some groups have already begun to evaluate the
potential benefits of ApoA-I mimetics in AD, observing benefits with respect to astrogliosis, amyloid
pathology, CAA, and whole brain neuroinflammation [169–171]. Additionally to the aforementioned
proteins, several AD genetic risk factors are immune-related genes [172–174]. Again, the presiding
focus pertains to the relationship of these genes to parenchymal amyloid, with little consideration to
vascular amyloid deposition. For instance, TREM2, one of the most studied AD-immune risk factors,
has always been analyzed in the context of parenchymal amyloid [175–179]. This is also the case for
genes such as CR1, ABCA7, CD33, MEF2C, HLA-DRB1/DRB5, TRIP4, MS4A, EPHA1, and SPI1 [180,181].
Interestingly, recent genetic association studies of AD and other dementias have established correlations
between specific risk factors such as ABCA7, CR1, FERMT2, NME8, SLC24A4, SORL1, ZCWPW1, and
GALNT7 to CAA, with ABCA7 and CR1 having the strongest association [182], enhancing the necessity
of further cellular and molecular studies to dissect this relationship in detail.
5. Conclusions
Tau pathology and neuroinflammation have been identified as major contributors of
neurodegeneration associated with amyloid deposits in AD and AD-related dementias.
This contribution to amyloid pathology has been extensively studied in vivo utilizing animal
models characterized by the accumulation of extra- or intracellular accumulation of parenchymal
amyloid [103,104,179,183–186]. However, not many cellular and molecular studies have been
performed to determine the role of tau and neuroinflammation in dementias associated with
vascular amyloid accumulation, despite the fact that numerous pathological studies have suggested a
preponderant neuroinflammatory response and perivascular tau aggregation in patients and in vivo
models for CAA [19,50,95,118,187,188]. In this review, we discussed novel studies that link tau
aggregation and neuroinflammation to neurovascular pathologies such as CAA and suggest how the
“amyloid–tau–neuroinflammation” axis that has been studied in extensive detail in the context of
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parenchymal amyloid needs to be dissected in the context of vascular amyloid deposition, as seen in
Figure 1. Further studies on the involvement of tau and neuroinflammation on dementias associated
with CAA could open the opportunity to develop therapeutic interventions for CAA that are currently
being proposed for AD and AD-related dementias [183–185], as seen in Figure 1.
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proposed for AD and AD-related dementias [184–186], as seen in Figure 1. 
 
Figure 1. The amyloid-tau-neuroinflammation axis in the context of cerebral amyloid angiopathy 
(CAA). Amyloid accumulates in the vasculature, causing a destabilization of the neurovascular unit, 
translated in endothelial damage, pericyte decay, and perivascular macrophage, astrocyte, and 
microglial reaction. These series of events leads to neuroinflammation. Additionally, tau aggregates 
in astrocytes and neurons could contribute to neuroinflammation and neurodegeneration observed 
in CAA. A number of immune-related genes previously associated with AD and the inclusion of tau-
related events could be signaled as possible therapeutic targets and a useful tool to contain the 
detrimental consequences of CAA. 
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